KRAS inhibitors such as cetuximab in colorectal carcinoma, inhibitors of epidermal growth factor receptor such as fefitinib, osimertinib, afatinib and erlotinib in non-small-cell lung carcinoma (NSCLC), BCR-ABL tyrosine kinase inhibitors such as Imatinib mesylate in leukaemia, BRAF inhibitors such as encorafenib, dabrafenib and vemurafenib in melanomas, herceptin and tamoxifen in breast cancers have been extensively utilised in treatment of different cancer types [4]. Here, BRAF is linked to non-small cell lung carcinoma.